Drugs & Therapy Perspectives

, Volume 28, Issue 10, pp 6–11

Fingolimod: a guide to its use in multiple sclerosis in the EU

  • Lesley J. Scott
  • Katherine A. Lyseng-Williamson
Adis Drug Clinical Q&A

DOI: 10.1007/BF03262126

Cite this article as:
Scott, L.J. & Lyseng-Williamson, K.A. Drugs Ther Perspect (2012) 28: 6. doi:10.1007/BF03262126
  • 33 Downloads

Abstract

Fingolimod, a novel sphingosine 1-phosphate receptor agonist, is indicated for the treatment of patients with relapsing- remitting multiple sclerosis. In clinical trials, oral fingolimod was more effective than placebo and intramuscular interferon β-1a at reducing annualized relapse rates and the burden and activity of disease.

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Lesley J. Scott
    • 1
  • Katherine A. Lyseng-Williamson
    • 1
  1. 1.AdisAucklandNew Zealand